For more than 50 years, there has been considerable interest—and ongoing debate—as to the potential clinical benefits of interventions targeted to more intensively control elevated blood glucose levels in patients with acute myocardial infarction (MI) and, more recently, in those with acute coronary syndrome (ACS). In 1962, Sodi-Pallares et al introduced the glucose-insulin-potassium infusion (GIK) for treatment of acute MI.1,2 In 1972, Maroko and coworkers demonstrated a reduction in infarct size in dogs with experimental MI that were given an infusion of GIK.3 However, the use of GIK treatment for acute MI was largely abandoned over the ensuing years because of doubts and conflicting data about its efficacy, only to see interest return to this treatment when Diaz et al,4 on behalf of the Estudios Cardiológicos Latinoamérica (ECLA) Collaborative Group, showed a dramatic reduction in mortality after an acute MI from 11.5% in the control group to 6.7% in patients treated with GIK.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Internal Medicine editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination
Evidence Summary and Review 2
The Rational Clinical Examination
Multivariate Findings for ACI Syndromes
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.